KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price decline ... are also using CRISPR technology to address various ...

They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use their proprietary MarketBeat MaxCyte: Building the Future of Cell and Gene Therapy ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

InvestingPro data indicates significant stock price volatility with a ... of innovation in this space means that CRISPR must continuously advance its technology to maintain its competitive position.

The fall in CRSP stock ... think CRISPR Therapeutics (NASDAQ: CRSP) could more than double your money in the year ahead. If things don't work out, they can quietly lower their price targets ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

CRISPR Therapeutics ... could push the stock much higher. Investment bank analysts also expect Iovance Biotherapeutics (NASDAQ: IOVA) to soar in 2025. Before chasing exciting price targets ...